Baxa Corporation And Carmel Pharma AB End Exclusive Distribution Agreement For PhaSeal(R)
Published: Nov 14, 2005
ENGLEWOOD, Colo., Nov. 14 /PRNewswire/ -- Baxa Corporation announced today that its exclusive US distribution rights for the PhaSeal Products will end on December 31, 2005. The products' Swedish manufacturer, Carmel Pharma ab, has elected not to continue the agreement. Over the course of the agreement, Baxa more than tripled annual PhaSeal product sales. Today, PhaSeal is used in more than 300 leading cancer treatment facilities nationwide.
Carmel Pharma ab will establish a US headquarters to take over the marketing, sales and distribution activities for PhaSeal. Customers, wholesalers and Group Purchasing Organizations were notified of the distribution change effective January 1, 2006.
PhaSeal is the only documented, closed system for safe handling of hazardous drugs. Its unique design contains drug aerosols and prevents leakage from drug preparation to transport to administration and disposal. "Baxa is proud to have played an important role in raising the awareness of the risks of handling hazardous medications for leading US hospitals and clinics," notes Greg Baldwin, Baxa Chairman and CEO. "We are committed to doing our part to ensure a smooth transition for these customers."
Launched in the US in December, 2000, PhaSeal is used in nearly all of the top national cancer centers, including MD Anderson Cancer Center in Houston. A body of medical and research studies supports the use of closed systems such as PhaSeal to ensure the safety of nurses and technicians responsible for mixing and administering hazardous drugs.
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver- based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has offices and subsidiaries in Canada, the United Kingdom and Denmark; and distribution partners worldwide. Further information is available at www.baxa.com.
About Carmel Pharma
Carmel Pharma ab manufactures the PhaSeal closed-system products at its headquarters in Goteborg, Sweden. Active in the market since 1994, PhaSeal is now used in most Swedish hospitals, and its benefits are backed by a significant body of scientific research on the health risks related to preparation and administration of cytotoxic drugs. The PhaSeal System is protected by a comprehensive patent portfolio in the US, European Union and Japan. More information is available at www.carmelpharma.se.
Contacts: Marian Robinson, Vice President, Marketing Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157 Email: firstname.lastname@example.org Maggie Chamberlin Holben, APR Absolutely Public Relations: 303.984.9801 or 303.669.3558 Email: email@example.comBaxa Corporation
CONTACT: Marian Robinson, Vice President, Marketing of Baxa Corporation,+1-800-567-2292, ext. 2157, or +1-303-617-2157, firstname.lastname@example.org;or Maggie Chamberlin Holben, APR of Absolutely Public Relations,+1-303-984-9801, or +1-303-669-3558, email@example.com, for BaxaCorporation